Consumer Health Education & Advocacy Training
From undiagnosed to optimally treated
BlueRipple Health equips you to understand your options for detecting, diagnosing, and treating coronary artery disease — and to advocate for yourself within a system that rewards proactivity.
Portal
In-depth, independent research across the full decision sequence.
Topics
CT Angiogram
The optimal balance between diagnostic accuracy, safety, and cost-effectiveness.
PCSK9 Inhibitors
A fundamentally different approach to lowering LDL cholesterol.
Lp(a)
The inherited risk factor most doctors never test for.
Research
Banach et al., 2025 · Meta-analysis
Statin–Ezetimibe Combination Therapy vs Statin Monotherapy on Cardiovascular Outcomes: A Meta-Analysis
Adding ezetimibe to a statin cut cardiovascular events and deaths beyond a statin alone — a combination that is cheap, generic, and underused.
Sehayek et al., 2025 · Systematic review
ApoB, LDL-C, and Non-HDL-C as Markers of Cardiovascular Risk: A Systematic Review of Discordance Analyses
Across more than 590,000 people, apoB tracked cardiovascular risk more faithfully than LDL-C or non-HDL-C wherever the measures disagreed.
Ryan et al., 2024 · Prespecified analysis of randomized trial
Long-Term Weight Loss Effects of Semaglutide in Obesity Without Diabetes in the SELECT Trial
In adults with obesity but not diabetes, semaglutide produced sustained weight loss across four years — without the rebound most diets bring.
Take control of your heart health.
Get annual access to the Portal — a comprehensive, independent analysis of every option available for coronary artery disease.
Get Annual Access — $199/yr